+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Point of Care Diagnostics Market Size, Share & Trends Analysis Report by Product (Glucose Testing, Blood Gas/ Electrolytes, Cancer Marker), by End Use (Clinics, Hospital), by Region, and Segment Forecasts, 2020 - 2027

  • ID: 4479669
  • Report
  • March 2020
  • Region: Global
  • 250 pages
  • Grand View Research
1 of 3

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • Abaxis, Inc.
  • Beckman Coulter, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Nipro Diagnostics Inc.
  • QIAGEN
  • Sekisui Diagnostics LLC
  • MORE
The global point of care diagnostics market size is expected to reach USD 24.1 billion by 2027, expanding at a CAGR of 3.2%. Continuous advancement in the development of highly sensitive and specific miniaturized biosensors, based on microfluidic systems along with handheld devices, is anticipated to drive the market. These systems are capable of automation, integration, and multiplex detection, suitable for use in areas without well-trained professionals.

These tests have emerged as an indispensable part of modern healthcare, as it improves the quality, accuracy, availability, and affordability of patient care. The uptake of POC devices is rapidly progressing due to the incorporation of advanced technologies. For instance, in July 2019, HiberGene Diagnostics has outlined plans to develop a cost-effective POC testing system based on its licensed loop-mediated isothermal amplification technology.

The growing popularity of rapid testing in near-patient settings has positively impacted point of care testing market growth. The rise in investments to develop advanced rapid testing devices, such as single integrated user-friendly devices, fuels market progression. For instance, in February 2019, the Global Health Investment Fund (GHIF) granted USD 6 million to Atomo Diagnostics for the commercialization of its AtomoRapid diagnostic test platform.

Further key findings from the report suggest:
  • Glucose testing accounted for the largest revenue share owing to the high incidence rate of diabetes and the abundant usage of portable glucose meters
  • Cancer markers are expected to witness the fastest growth rate due to the extensive ongoing R&D activities related to cancer and growing demand for circulating tumor cells (CTC) - based cancer detection
  • POC tests offer several benefits as compared to conventional lab tests that lead to their high utilization rate in clinics, resulting in the largest revenue share of clinics
  • These benefits include reduced turnaround testing timeline, delivery of on-site results, minimal contact with clinical staff, and faster diagnosis
  • Continuous development of point of care devices, especially glucose meters, for home care settings, early detection, and prevention of diseases is expected to drive the home segment at the fastest growth rate
  • North America dominated the point of care testing market owing to the favorable government initiatives and programs related to lipid and blood sugar level testing that encourage the usage rate of point of care tests in this region
  • Key participants operating in this market include Danaher, Abbott Laboratories, bioMérieux SA, Trividia Health, Inc., QIAGEN, F. Hoffmann-La Roche Ltd., and Siemens
  • Companies are adopting several strategic developments related to the development of biosensors for point of care settings
  • For instance, in September 2019, BioMed X completed its collaboration with Roche Diagnostics for the development of nanomaterial-based biosensors for point of care testing

Please note: This product will be delivered within 48 business hours after receipt of order.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Abaxis, Inc.
  • Beckman Coulter, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Nipro Diagnostics Inc.
  • QIAGEN
  • Sekisui Diagnostics LLC
  • MORE
Chapter 1 Executive Summary

Chapter 2 Research Methodology
2.1 Information procurement
2.2 Data Analysis

Chapter 3 Market Variables, Trends & Scope
3.1 Market Segmentation & Scope
3.1.1 Market driver analysis
3.1.1.1 Introduction of CLIA waived tests
3.1.1.2 Rise in funding from government and private institutions
3.1.1.3 Growing geriatric population base
3.1.1.4 Growing prevalence of target diseases
3.1.1.5 Growing demand for home healthcare and the introduction of advance technology enabled products
3.1.2 Market restraint analysis
3.1.2.1 High procedure costs coupled with limited adoption of POC devices in certain emerging regions
3.1.2.2 Presence of ambiguous regulatory as well as reimbursement framework for primary care setting
3.1.3 Market challenge analysis
3.1.3.1 POC devices pose challenges in maintaining the quality standards
3.2 Penetration & Growth Prospect Mapping
3.2.1 Penetration & growth prospect mapping for point of care end-use, 2019
3.3 Point of care Diagnostics/Testing SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
3.4 Industry Analysis - Porter’s
3.5 Major Deals & Strategic Alliances Analysis
3.5.1 Joint ventures
3.5.2 Mergers & acquisitions
3.5.3 Licensing & partnership
3.5.4 Market entry strategies
3.6 Price-Cost-Margin Analysis for Point of care Diagnostics/Testing
3.7 Point of care Diagnostics/Testing: Market influencers
3.7.1 High sensitivity
3.7.2 Shift to molecular diagnostics
3.8 Product Positioning Analysis, 2019
3.8.1 Glucose testing
3.8.2 Hb1Ac testing
3.8.3 Coagulation testing
3.8.4 Fertility
3.8.5 Infectious disease
3.8.6 Cardiac markers
3.8.7 Thyroid
3.8.8 Haematology
3.8.9 Primary care
3.8.10 Decentralized clinical chemistry
3.8.11 Faecal
3.8.12 Lipid testing
3.8.13 Cancer marker
3.8.14 Blood gas/electrolytes
3.8.15 Ambulatory chemistry
3.8.16 Drug of Abuse (DOA) testing
3.8.17 Urinalysis
3.9 Marketing Channels
3.9.1 Abbott Laboratories
3.9.1.1 Abbott Laboratories: Marketing channels & distribution network for POC
3.9.1.2 Alere Inc.
3.9.1.2.1 Alere: Marketing channels & distribution network for POC
3.9.2 Roche Diagnostics
3.9.2.1 Roche Diagnostics: Marketing channels & distribution network for POC
3.9.3 Siemens
3.9.3.1 Siemens: Marketing channels & distribution network for POC
3.9.4 Danaher
3.9.4.1 Danaher: Marketing channels & distribution network for POC
3.9.5 Instrumentation Laboratory Spa.
3.9.5.1 Instrumentation Laboratory Spa.: Marketing channels & distribution network for POC
3.9.6 Becton Dickinson
3.9.6.1 Becton Dickinson.: Marketing channels & distribution network for POC
3.10 Regulatory Framework Analysis for U.S. Point of Care Diagnostics
3.11 Regulatory Framework Analysis for Europe Point of Care Diagnostics
3.12 Regulatory Framework Analysis for Japan Point of Care Diagnostics

Chapter 4 Competitive Analysis
4.1 Recent Developments & Impact Analysis, by Key Market Participants
4.2 Company/Competition Categorization
4.3 Company Market Position Analysis
4.3.1 Company size
4.3.2 Distribution network
4.3.3 Product portfolio
4.3.4 Segment coverage
4.3.5 Geographic presence
4.3.6 Collaborations
4.3.7 Conclusion
4.4 Market Differentiators
4.4.1 Application trends
4.4.2 Technology trends
4.4.3 Test location trends
4.4.4 End-use trends
4.4.5 Regional trends
4.5 New Entrants/Emerging players

Chapter 5 Point of care Diagnostics/ Testing Market: Product Estimates & Trend Analysis
5.1 Point of care diagnostics/testing market: Product Movement Analysis
5.2 Point of care Glucose Diagnostics/Testing
5.2.1 Global point of care glucose diagnostics/testing, 2016 - 2027 (USD Million)
5.3 Hb1Ac Testing.
5.3.1 Global point of care Hb1Ac diagnostics/testing, 2016 - 2027 (USD Million)
5.4 Point of care Coagulation Diagnostics/Testing
5.4.1 Global point of care coagulation diagnostics/testing market, 2016 - 2027 (USD Million)
5.5 Point of care Fertility Diagnostics/Testing
5.5.1 Global point of care fertility diagnostics/testing, 2016 - 2027 (USD Million)
5.6 Point of care Infectious Disease Diagnostics/Testing
5.6.1 Global point of care infectious disease diagnostics/testing, 2016 - 2027 (USD Million)
5.6.2 HIV POC testing
5.6.2.1 Global HIV point of care diagnostics/testing market, 2016 - 2027 (USD Million)
5.6.3 Clostridium difficile point of care diagnostics/testing
5.6.3.1 Global Clostridium difficile point of care diagnostics/testing market, 2016 - 2027 (USD Million)
5.6.4 HBV POC testing point of care diagnostics/testing
5.6.4.1 Global HBV point of care diagnostics/testing market, 2016 - 2027 (USD Million)
5.6.5 Pneumonia or streptococcus associated infections
5.6.5.1 Global pneumonia or streptococcus associated infections Point of care diagnostics/testing market, 2016 - 2027 (USD Million)
5.6.6 Respiratory syncytial virus (RSV) point of care diagnostics/testing
5.6.6.1 Global respiratory syncytial virus (RSV) point of care diagnostics/testing market, 2016 - 2027 (USD Million)
5.6.7 HPV point of care diagnostics/testing
5.6.7.1 Global HPV point of care diagnostics/testing market, 2016 - 2027 (USD Million)
5.6.8 Influenza/flu point of care diagnostics/testing
5.6.8.1 Global influenza/flu point of care diagnostics/testing market, 2016 - 2027 (USD Million)
5.6.9 HCV point of care diagnostics/testing
5.6.9.1 Global HCV point of care diagnostics/testing market, 2016 - 2027 (USD Million)
5.6.10 MRSA point of care diagnostics/testing
5.6.10.1 Global MRSA point of care diagnostics/testing market, 2016 - 2027 (USD Million)
5.6.11 TB and drug-resistant TB point of care diagnostics/testing
5.6.11.1 Global TB and drug-resistant TB point of care diagnostics/testing market, 2016 - 2027 (USD Million)
5.6.12 HSV point of care diagnostics/testing
5.6.12.1 Global HSV point of care diagnostics/testing market, 2016 - 2027 (USD Million)
5.6.13 Other infectious diseases point of care diagnostics/testing
5.6.13.1 Global other infectious diseases point of care diagnostics/testing market, 2016 - 2027 (USD Million)
5.7 Point of care Diagnostics/Testing Cardiac Markers
5.7.1 Global point of care diagnostics/testing cardiac markers market, 2016 - 2027 (USD Million)
5.8 Point of care Diagnostics/Testing Thyroid Testing
5.8.1 Global point of care diagnostics/testing thyroid testing market, 2016 - 2027 (USD Million)
5.9 Hematology Point of care Diagnostics/Testing
5.9.1 Global haematology point of care diagnostics/testing market, 2016 - 2027 (USD Million)
5.10 Primary Care Systems
5.10.1 Global primary care systems point of care diagnostics/testing market, 2016 - 2027 (USD Million)
5.11 Decentralized clinical chemistry point of care diagnostics/testing
5.11.1 Global decentralized clinical chemistry point of care diagnostics/testing market, 2016 - 2027 (USD Million)
5.12 Feces POC Testing
5.12.1 Global feces point of care diagnostics/testing market, 2016 - 2027 (USD Million)
5.13 Lipid POC
5.13.1 Global lipid point of care diagnostics/testing market, 2016 - 2027 (USD Million)
5.14 Cancer Marker
5.14.1 Global cancer marker testing market, 2016 - 2027 (USD Million)
5.15 Blood Gas/Electrolytes
5.15.1 Global blood gas/electrolytes Point of care diagnostics/testing market, 2016 - 2027 (USD Million)
5.16 Ambulatory Chemistry
5.16.1 Global ambulatory chemistry Point of care diagnostics/testing market, 2016 - 2027 (USD Million)
5.17 Drug Abuse Point of care Diagnostics/Testing
5.17.1 Global drug abuse point of care diagnostics/testing market, 2016 - 2027 (USD Million)
5.18 Urinalysis Point of care Diagnostics/Testing
5.18.1 Global urinalysis Point of care diagnostics/testing market, 2016 - 2027 (USD Million)

Chapter 6 Point of care Diagnostics/ Testing Market: End-use Estimates & Trend Analysis
6.1 Point of care diagnostics/testing market: End-use movement analysis
6.2 Clinics
6.2.1 Global primary care clinics market, 2016 - 2027 (USD Million)
6.2.2 Pharmacy & retail clinicS
6.2.2.1 Global pharmacy & retail clinics market, 2016 - 2027 (USD Million)
6.2.3 Phsician office
6.2.3.1 Global phsician office market, 2016 - 2027 (USD Million)
6.2.4 Urgent care clinics
6.2.4.1 Global urgent care clinics market, 2016 - 2027 (USD Million)
6.2.5 Non-practice clinics
6.2.5.1 Global non-practice clinics market, 2016 - 2027 (USD Million)
6.3 Hospitals
6.3.1 Global hospitals market, 2016 - 2027 (USD Million)
6.4 Home
6.4.1 Global home point of care diagnostics/testing market, 2016 - 2027 (USD Million)
6.5 Assisted Living Healthcare Facilities
6.5.1 Global assisted living healthcare facilities market, 2016 - 2027 (USD Million)
6.6 Laboratory
6.6.1 Global laboratory market, 2016 - 2027 (USD Million)

Chapter 7 Point of care Diagnostics/ Testing Market: Regional Estimates & Trend Analysis for Product & End-use
7.1 Point of care diagnostics/testing market Share by Region, 2019 & 2027
7.2 North America
7.2.1 North America point of care diagnostics/testing market, 2016 - 2027 (USD Million)
7.2.2 U.S.
7.2.2.1 U.S. point of care diagnostics/testing market, by product, 2016 - 2027 (USD Million)
7.2.2.2 U.S. point of care diagnostics/testing market, by end use, 2016 - 2027 (USD Million)
7.2.3 Canada
7.2.3.1 Canada point of care diagnostics/testing market, by product, 2016 - 2027 (USD Million)
7.2.3.2 Canada point of care diagnostics/testing market, by end use, 2016 - 2027 (USD Million)
7.3 Europe
7.3.1 Europe point of care diagnostics/testing market, 2016 - 2027 (USD Million)
7.3.2 Germany
7.3.2.1 Germany point of care diagnostics/testing market, by product, 2016 - 2027 (USD Million)
7.3.2.2 Germany point of care diagnostics/testing market, by end use, 2016 - 2027 (USD Million)
7.3.3 U.K.
7.3.3.1 U.K. point of care diagnostics/testing market, by product, 2016 - 2027 (USD Million)
7.3.3.2 U.K. point of care diagnostics/testing market, by end use, 2016 - 2027 (USD Million)
7.3.4 France
7.3.4.1 France point of care diagnostics/testing market, by product, 2016 - 2027 (USD Million)
7.3.4.2 France point of care diagnostics/testing market, by end use, 2016 - 2027 (USD Million)
7.3.5 Italy
7.3.5.1 Italy point of care diagnostics/testing market, by product, 2016 - 2027 (USD Million)
7.3.5.2 Italy point of care diagnostics/testing market, by end use, 2016 - 2027 (USD Million)
7.3.6 Spain
7.3.6.1 Spain point of care diagnostics/testing market, by product, 2016 - 2027 (USD Million)
7.3.6.2 Spain point of care diagnostics/testing market, by end use, 2016 - 2027 (USD Million)
7.3.7 Russia
7.3.7.1 Russia point of care diagnostics/testing market, by product, 2016 - 2027 (USD Million)
7.3.7.2 Russia point of care diagnostics/testing market, by end use, 2016 - 2027 (USD Million)
7.4 Asia Pacific
7.4.1 Asia Pacific point of care diagnostics/testing market, 2016 - 2027 (USD Million)
7.4.2 Japan
7.4.2.1 Japan point of care diagnostics/testing market, by product, 2016 - 2027 (USD Million)
7.4.2.2 Japan point of care diagnostics/testing market, by end use, 2016 - 2027 (USD Million)
7.4.3 China
7.4.3.1 China point of care diagnostics/testing market, by product, 2016 - 2027 (USD Million)
7.4.3.2 China point of care diagnostics/testing market, by end use, 2016 - 2027 (USD Million)
7.4.4 India
7.4.4.1 India point of care diagnostics/testing market, by product, 2016 - 2027 (USD Million)
7.4.4.2 India point of care diagnostics/testing market, by end use, 2016 - 2027 (USD Million)
7.4.5 Australia
7.4.5.1 Australia point of care diagnostics/testing market, by product, 2016 - 2027 (USD Million)
7.4.5.2 Australia point of care diagnostics/testing market, by end use, 2016 - 2027 (USD Million)
7.4.6 Korea
7.4.6.1 Korea point of care diagnostics/testing market, by product, 2016 - 2027 (USD Million)
7.4.6.2 Korea point of care diagnostics/testing market, by end use, 2016 - 2027 (USD Million)
7.4.7 Singapore
7.4.7.1 Singapore point of care diagnostics/testing market, by product, 2016 - 2027 (USD Million)
7.4.7.2 Singapore point of care diagnostics/testing market, by end use, 2016 - 2027 (USD Million)
7.5 Latin America
7.5.1 Latin America point of care diagnostics/testing market, 2016 - 2027 (USD Million)
7.5.2 Brazil
7.5.2.1 Brazil point of care diagnostics/testing market, by product, 2016 - 2027 (USD Million)
7.5.2.2 Brazil point of care diagnostics/testing market, by end use, 2016 - 2027 (USD Million)
7.5.3 Mexico
7.5.3.1 Mexico point of care diagnostics/testing market, by product, 2016 - 2027 (USD Million)
7.5.3.2 Mexico point of care diagnostics/testing market, by end use, 2016 - 2027 (USD Million)
7.5.4 Argentina
7.5.4.1 Argentina point of care diagnostics/testing market, by product, 2016 - 2027 (USD Million)
7.5.4.2 Argentina point of care diagnostics/testing market, by end use, 2016 - 2027 (USD Million)
7.5.5 Chile
7.5.5.1 Chile point of care diagnostics/testing market, by product, 2016 - 2027 (USD Million)
7.5.5.2 Chile point of care diagnostics/testing market, by end use, 2016 - 2027 (USD Million)
7.6 Middle East & Africa.
7.6.1 Middle East & Africa point of care diagnostics/testing market, 2016 - 2027 (USD Million)
7.6.2 South Africa
7.6.2.1 South Africa point of care diagnostics/testing market, by product, 2016 - 2027 (USD Million)
7.6.2.2 South Africa point of care diagnostics/testing market, by end use, 2016 - 2027 (USD Million)
7.6.3 Saudi Arabia
7.6.3.1 Saudi Arabia point of care diagnostics/testing market, by product, 2016 - 2027 (USD Million)
7.6.3.2 Saudi Arabia point of care diagnostics/testing market, by end use, 2016 - 2027 (USD Million)
7.6.4 Kenya
7.6.4.1 Kenya point of care diagnostics/testing market, by product, 2016 - 2027 (USD Million)
7.6.4.2 Kenya point of care diagnostics/testing market, by end use, 2016 - 2027 (USD Million)
7.6.5 Nigeria
7.6.5.1 Nigeria point of care diagnostics/testing market, by product, 2016 - 2027 (USD Million)
7.6.5.2 Nigeria point of care diagnostics/testing market, by end use, 2016 - 2027 (USD Million)
7.6.6 Zimbabwe
7.6.6.1 Zimbabwe point of care diagnostics/testing market, by product, 2016 - 2027 (USD Million)
7.6.6.2 Zimbabwe point of care diagnostics/testing market, by end use, 2016 - 2027 (USD Million)
7.6.7 UAE
7.6.7.1 UAE point of care diagnostics/testing market, by product, 2016 - 2027 (USD Million)
7.6.7.2 UAE point of care diagnostics/testing market, by end use, 2016 - 2027 (USD Million)
7.6.8 Qatar
7.6.8.1 Qatar point of care diagnostics/testing market, by product, 2016 - 2027 (USD Million)
7.6.7.2 Qatar point of care diagnostics/testing market, by end use, 2016 - 2027 (USD Million)

Chapter 8 Competitive Landscape
8.1 Company Profile
8.1.1 F. Hoffmann-La Roche Ltd.
8.1.1.1 Company overview
8.1.1.2 Financial performance
8.1.1.3 Product benchmarking
8.1.1.4 Strategic initiatives
8.1.2 Abbott
8.1.2.1 Company overview
8.1.2.1.1 Alere, Inc.
8.1.2.2 Financial performance
8.1.2.3 Product benchmarking
8.1.2.4 Strategic initiatives
8.1.3 Siemens
8.1.3.1 Company overview
8.1.3.2 Financial performance
8.1.3.3 Product benchmarking
8.1.3.4 Strategic initiatives
8.1.4 Danaher
8.1.4.1 Company overview
8.1.4.1.1 Beckman Coulter, Inc.
8.1.4.1.2 Radiometer Medical ApS
8.1.4.1.3 HemoCue AB
8.1.4.2 Financial performance
8.1.4.3 Product benchmarking
8.1.4.4 Strategic initiatives
8.1.5 bioMérieux SA
8.1.5.1 Company overview
8.1.5.2 Financial performance
8.1.5.3 Product benchmarking
8.1.5.4 Strategic initiatives
8.1.6 Johnson & Johnson
8.1.6.1 Company overview
8.1.6.2 Financial performance
8.1.6.3 Product benchmarking
8.1.6.4 Strategic initiatives
8.1.7 Abaxis, Inc.
8.1.7.1 Company overview
8.1.7.2 Financial performance
8.1.7.3 Product benchmarking
8.1.7.4 Strategic initiatives
8.1.8 QIAGEN
8.1.8.1 Company overview
8.1.8.2 Financial performance
8.1.8.3 Product benchmarking
8.1.8.4 Strategic initiatives
8.1.9 Instrumentation Laboratory
8.1.9.1 Company overview
8.1.9.2 Accriva Diagnostics
8.1.9.3 Financial performance
8.1.9.4 Product benchmarking
8.1.9.5 Strategic initiatives
8.1.10 Nova Biomedical
8.1.10.1 Company overview
8.1.10.2 Financial performance
8.1.10.3 Product benchmarking
8.1.10.4 Strategic initiatives
8.1.11 Trividia Health, Inc.
8.1.11.1 Company overview
8.1.11.2 Financial performance
8.1.11.3 Product benchmarking
8.1.11.4 Strategic initiatives
8.1.12 Quidel Corporation
8.1.12.1 Company overview
8.1.12.2 Financial performance
8.1.12.3 Product benchmarking
8.1.12.4 Strategic initiatives
8.1.13 Trinity Biotech
8.1.13.1 Company overview
8.1.13.2 Financial performance
8.1.13.3 Product benchmarking
8.1.13.4 Strategic initiatives
8.1.14 Sekisui Diagnostics LLC
8.1.14.1 Company overview
8.1.14.2 Financial performance
8.1.14.3 Product benchmarking
8.1.14.4 Strategic initiatives
8.1.15 OraSure Technologies Inc.
8.1.15.1 Company overview
8.1.15.2 Financial performance
8.1.15.3 Product benchmarking
8.1.15.4 Strategic initiatives
8.1.16 Becton Dickinson & Company (BD)
8.1.16.1 Company overview
8.1.16.2 Financial performance
8.1.16.3 Product benchmarking
8.1.16.4 Strategic initiatives
8.1.17 Nipro Diagnostics Inc.
8.1.17.1 Company overview
8.1.17.2 Financial performance
8.1.17.3 Product benchmarking
8.1.17.4 Strategic initiatives
8.1.18 Spectral Medical, Inc.
8.1.18.1 Company overview
8.1.18.2 Financial performance
8.1.18.3 Product benchmarking
8.1.18.4 Strategic initiatives



*Full List of Tables and Figures Available on Enquiry.
Note: Product cover images may vary from those shown
3 of 3
  • F. Hoffmann-La Roche Ltd.
  • Abbott
  • Alere, Inc.
  • Siemens
  • Danaher
  • Beckman Coulter, Inc.
  • Radiometer Medical ApS
  • HemoCue AB
  • bioMérieux SA
  • Johnson & Johnson
  • Abaxis, Inc.
  • QIAGEN
  • Instrumentation Laboratory
  • Nova Biomedical
  • Trividia Health, Inc.
  • Quidel Corporation
  • Trinity Biotech
  • Sekisui Diagnostics LLC
  • OraSure Technologies Inc.
  • Becton Dickinson & Company (BD)
  • Nipro Diagnostics Inc.
  • Spectral Medical, Inc.
Note: Product cover images may vary from those shown
Adroll
adroll